Skip to main content
Arjan Diepstra
dr.

As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.

Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach
Published in: Cancers
Simple Summary This review summarizes gene-expression profiling insights into the background and origination of diffuse large B-cell lymphomas (DLBCL). To further unravel the molecular biology of these lymphomas, a consortium panel called BLYM-777 was designed including genes important for subtype classifications, genetic pathways, tumor-microenvironment, immune response and resistance to targeted therapies. This review proposes to combine this transcriptomic method with genomics, proteomics, and patient characteristics to facilitate diagnostic classification, prognostication, and the development of new targeted therapeutic strategies in DLBCL. Gene-expression profiling (GEP) is used to study the...
Fleur A de Groot, Ruben A L de Groen, Anke van den Berg, Patty M Jansen, King H Lam, Pim G N J Mutsaers, Carel J M van Noesel, Martine E D Chamuleau, Wendy B C Stevens, Jessica R Plaça, Rogier Mous, Marie José Kersten, Marjolein M W van der Poel, Thomas Tousseyn, F J Sherida H Woei-A-Jin, Arjan Diepstra, Marcel Nijland, Joost S P Vermaat
Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma
Published in: Cancers
Multiple gene expression profiles have been identified in diffuse large B-cell lymphoma (DLBCL). Besides the cell of origin (COO) classifier, no signatures have been reproduced in independent studies or evaluated for capturing distinct aspects of DLBCL biology. We reproduced 4 signatures in 175 samples of the HOVON-84 trial on a panel of 117 genes using the NanoString platform. The four gene signatures capture the COO, MYC activity, B-cell receptor signaling, oxidative phosphorylation, and immune response. Performance of our classification algorithms were confirmed in the original datasets. We were...
Jessica Rodrigues Plaça, Arjan Diepstra, Tjitske Los, Matías Mendeville, Annika Seitz, Pieternella J Lugtenburg, Josée Zijlstra, King Lam, Wilson Araújo da Silva, Bauke Ylstra, Daphne de Jong, Anke van den Berg, Marcel Nijland
Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas
Published in: Virchows Archiv : an International Journal of Pathology
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) and primary cutaneous follicle center lymphoma with a diffuse population of large cells (PCFCL-LC) are both primary cutaneous B-cell lymphomas with large-cell morphology (CLBCL) but with different clinical characteristics and behavior. In systemic diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS), gene-expression profiling (GEP) revealed two molecular subgroups based on their cell-of-origin (COO) with prognostic significance: the germinal center B-cell-like (GCB) subtype and the activated B-cell-like (ABC) subtype. This study investigated whether COO classification is a useful tool for...
Anne M R Schrader, Ruben A L de Groen, Rein Willemze, Patty M Jansen, Koen D Quint, Tom van Wezel, Ronald van Eijk, Dina Ruano, Cornelis P Tensen, Esther Hauben, F J S H Woei-A-Jin, Anne M Busschots, Anke van den Berg, Arjan Diepstra, Maarten H Vermeer, Joost S P Vermaat
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
Published in: Leukemia
While classical Hodgkin lymphoma (HL) is highly susceptible to anti-programmed death protein 1 (PD1) antibodies, the exact modes of action remain controversial. To elucidate the circulating lymphocyte phenotype and systemic effects during anti-PD1 1st-line HL treatment we applied multicolor flow cytometry, FluoroSpot and NanoString to sequential samples of 81 HL patients from the NIVAHL trial (NCT03004833) compared to healthy controls. HL patients showed a decreased CD4 T-cell fraction, a higher percentage of effector-memory T cells and higher expression of activation markers at baseline. Strikingly, and in contrast to...
Maria A. Garcia-Marquez, Martin Thelen, Sarah Reinke, Diandra Keller, Kerstin Wennhold, Jonas Lehmann, Johanna Veldman, Sven Borchmann, Andreas Rosenwald, Stephanie Sasse, Arjan Diepstra, Peter Borchmann, Andreas Engert, Wolfram Klapper, Michael Von Bergwelt-Baildon, Paul J. Broeckelmann, Hans A. Schloesser
A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma
Published in: Blood
Classical Hodgkin lymphoma (cHL) is a common malignancy in children and adolescents. Although cHL is highly curable, treatment with chemotherapy and radiation often come at the cost of long-term toxicity and morbidity. Effective risk-stratification tools are needed to tailor therapy. Here, we used gene expression profiling (GEP) to investigate tumor microenvironment (TME) biology, to determine molecular correlates of treatment failure, and to develop an outcome model prognostic for pediatric cHL. A total of 246 formalinfixed, paraffin-embedded tissue biopsies from patients enrolled in the Children’s Oncology Group trial AHOD0031...
Rebecca L. Johnston, Anja Mottok, Fong Chun Chan, Aixiang Jiang, Arjan Diepstra, Lydia Visser, Adele Telenius, Randy D. Gascoyne, Debra L. Friedman, Cindy L. Schwartz, Kara M. Kelly, David W. Scott, Terzah M. Horton, Christian Steidl